Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pirtobrutinib 3Cyclophosphamide 3Azacitidine 3ibrutinib 2fludarabine 2Mycophenolic Acid 2Lenalidomide 2zanubrutinib 1venetoclax 1ruxolitinib 1ponatinib 1nilotinib 1idelalisib 1idecabtagene vicleucel 1fludarabine phosphate 1cedazuridine 1cc-486 1asciminib 1acalabrutinib 1Whole-Body Irradiation 1Vancomycin 1Tretinoin 1Tacrolimus 1Sirolimus 1Semen Analysis 1Rituximab 1Quality of Life 1Physical Examination 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × cedazuridine × 90 days × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡